Revenue Dependence on Etuary in China
First written in FY2016-Q2. 12 of 24 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1ReframedAnnual report
「本件買収により、当社グループは日本における製薬事業基盤を獲得し、日本、米国及び中国を主要拠点とするグローバルな事業体制を強化いたしました。」
従来の中国アイスーリュイ及びF351中心の事業構成に加え、あゆみ製薬ホールディングスの買収により、日本、米国及び中国を主要拠点とする事業体制へ広げる説明が加わった。 - FY2025-H1ReframedAnnual report
「製薬及び創薬事業におきまして、当社グループの主要子会社であるGyre Pharmaceuticals Co., Ltd.（北京コンチネント）（以下「GYRE Pharmaceuticals」）は希少疾患分野（オーファンドラッグ）において、中国にて開発を進めていた慢性肝疾患（CLD）による血小板減少症と慢性特発性血小板減少症（ITP）の治療薬であるContiva（アバトロンボパグマレイン酸塩錠）を2025年３月に販売を開始いたしました。また、全身性硬化症に伴う間質性肺疾患（SSc-ILD）と進行性線維性間質性肺疾患(PF-ILD)の適応症をもつEtorel（ニンテダニブエシル酸塩ソフトカプセル）の製造販売に関する権利を2024年５月に取得し、2025年６月より販売を開始いたしました。GYRE Pharmaceuticalsは2025年６月までの３か月においてContivaとEtorelの売上はそれぞれ226百万円、242百万円となりました。」
収益源の説明がアイスーリュイとF351中心の構成から、Contiva及びEtorelの販売開始と売上、F230第1相試験開始を含む製品・開発構成へ広がった。 - FY2024F351臨床試験完了を反映Annual report
「医薬品事業では、中国市場で販売しているアイスーリュイ及び臨床試験が完了したF351を主力とする開発化合物の研究開発及び製造販売を行っております。」
医薬品事業の主力は引き続き中国のアイスーリュイであり、開発品についてはF351の臨床試験が完了した段階として説明されている。 - FY2024-H1Increase in consolidated subsidiaries and consolidation of an investment partnershipAnnual report
「Our group consists of the company, which prepares consolidated financial statements, 18 consolidated subsidiaries and 2 equity-method associates. Its business activities are classified into the pharmaceuticals business and the medical devices business. In the pharmaceuticals business, we conduct research and development, manufacturing and sales of Etuary, sold in the Chinese market, and development compounds centered on F351, which is undergoing clinical trials. In the medical devices business, based in the United States, we develop, manufacture and sell medical devices, including biomaterials.」
連結子会社数が17社から18社へ増加し、医薬品事業ではアイスーリュイ及びF351を中心とする開発化合物、医療機器事業では米国を拠点とする生体材料を扱う構成を継続している。 - FY2024-Q1Update to the consolidated group structureAnnual report
「当社グループは、連結財務諸表提出会社（以下「当社」）と、連結子会社17社及び関連会社２社により構成され、その事業内容を医薬品事業と医療機器事業に区分しております。医薬品事業では、中国市場で販売しているアイスーリュイ及び臨床試験中のF351を主力とする開発化合物の研究開発・製造・販売を行っております。医療機器事業では、米国を拠点とし医療機器（生体材料）の開発、製造及び販売を行っております。」
連結子会社数が17社となった一方、中国のアイスーリュイ及びF351を中心とする医薬品事業、米国を拠点とする医療機器事業という構成は維持されている。 - FY2023-Q1Update to the consolidated group structureAnnual report
「当社グループは、連結財務諸表提出会社（以下、当社という）と、連結子会社14社及び関連会社２社により構成され、その事業内容を医薬品事業と医療機器事業に区分しています。医薬品事業では、中国市場で販売しているアイスーリュイ及び臨床試験中のF351を主力とする開発化合物の研究開発・製造・販売を行っています。医療機器事業では、米国を拠点とし医療機器（生体材料）の開発、製造及び販売を行っています。」
従来の連結子会社15社という開示から、連結子会社14社及び関連会社2社という構成に更新されている。主力製品及びF351を中心とする医薬品事業、米国を拠点とする医療機器事業は継続している。 - FY2022-Q3RestatedAnnual report
「医薬品事業では、中国市場におけるアイスーリュイの製造・販売と、アイスーリュイの追加適応症及びF351を主力とする臨床試験活動を行っております。医療機器事業では、主に米国を拠点とし、当社グループが独自に開発した医療機器（生体材料）の製造及び販売を行っています。」
中国でアイスーリュイ及び追加適応症・F351の臨床試験、米国で生体材料を扱う医薬品・医療機器の二事業構成を再掲している。 - FY2022-Q1RestatedAnnual report
「Our group consists of the company, which prepares consolidated financial statements, and 15 consolidated subsidiaries. Its business activities are classified into the pharmaceuticals business and the medical devices business. In the pharmaceuticals business, we manufacture and sell Etuary in the Chinese market and conduct clinical trials focused on additional indications for Etuary and F351. In the medical devices business, based primarily in the United States, we manufacture and sell medical devices, including biomaterials, developed independently by our group.」
中国でアイスーリュイ及び追加適応症・F351の臨床試験、米国で生体材料を扱う医薬品・医療機器の2事業構成を再掲している。 - FY2021AdvancedAnnual report
「Etuary 6,938,730 9,690,910」
Etuary revenue increased to ¥9,690.910 million, reinforcing its position as the principal product in the pharmaceutical business and a major contributor to consolidated revenue. - FY2021-Q3RestatedAnnual report
「Our group consists of the company, which prepares consolidated financial statements, and 15 consolidated subsidiaries. Its business activities are classified into the pharmaceuticals business and the medical devices business. In the pharmaceuticals business, we manufacture and sell Etuary in the Chinese market and conduct clinical trials focused on additional indications for Etuary and F351. In the medical devices business, based primarily in the United States, we manufacture and sell medical devices, including biomaterials, developed independently by our group.」
The group reiterates its two-business structure, covering Etuary and clinical trials for additional indications and F351 in China and biomaterials in the United States. - FY2021-Q2RestatedAnnual report
「Our group consists of the company, which prepares consolidated financial statements, and 15 consolidated subsidiaries. Its business activities are classified into the pharmaceuticals business and the medical devices business.」
The group continues to comprise 15 consolidated subsidiaries and operate primarily through pharmaceutical and medical device businesses. - FY2021-Q1Increase to 15 consolidated subsidiariesAnnual report
「Our group consists of the company, which prepares consolidated financial statements, and 15 consolidated subsidiaries. Its business activities are classified into the pharmaceuticals business and the medical devices business.」
The number of consolidated subsidiaries increased from 13 to 15, while the two business segments, pharmaceuticals and medical devices, remained unchanged. - FY2020-Q2RestatedAnnual report
「Our group comprises the company filing consolidated financial statements and 13 consolidated subsidiaries, and its business activities are classified into pharmaceutical and medical device businesses. In the pharmaceutical business, we manufacture and sell Etuary in the Chinese market and conduct clinical trial activities focused on additional indications for Etuary and F351. In the medical device business, based in the United States, we manufacture and sell medical devices, including biomaterials, developed independently by our group.」
The group reiterates its two-business structure: manufacturing and selling Etuary in China and conducting clinical trials for additional indications and F351, while manufacturing and selling biomaterials in the United States. - FY2019RestatedAnnual report
「Our group comprises the company filing consolidated financial statements and 13 consolidated subsidiaries, and its business activities are classified into pharmaceutical and medical device businesses.」
The group continues to operate through two businesses, covering Etuary and F351 and other development compounds in China and biomaterials in the United States. - FY2019-Q2RestatedAnnual report
「Our group consists of the company filing consolidated financial statements (the Company) and 14 consolidated subsidiaries, and its business operations are classified into pharmaceutical operations and medical device operations. In pharmaceutical operations, we manufacture and sell Etuary in the Chinese market and conduct clinical trials focused on additional indications for Etuary and F351. In medical device operations, based in the United States, we manufacture and sell medical devices, including biomaterials, developed independently by our group.」
The group continues to comprise 14 consolidated subsidiaries and operate through two businesses, covering Etuary and development compounds in China and biomaterials in the United States. - FY2019-Q1Increase to 14 consolidated subsidiariesAnnual report
「Our group consists of the company filing consolidated financial statements (the Company) and 14 consolidated subsidiaries, and its business operations are classified into pharmaceutical operations and medical device operations. In pharmaceutical operations, we manufacture and sell Etuary in the Chinese market and conduct clinical trials focused on additional indications for Etuary and F351. In medical device operations, based in the United States, we manufacture and sell medical devices, including biomaterials, developed independently by our group.」
The number of consolidated subsidiaries increased from 10 to 14, while the two-business structure of pharmaceuticals and medical devices was maintained. - FY2018-Q3Increase in consolidated subsidiaries and addition of CullgenAnnual report
「Our group consists of the company filing consolidated financial statements (the Company) and 10 consolidated subsidiaries, and its business operations are classified into pharmaceutical operations and medical device operations. In pharmaceutical operations, we manufacture and sell Etuary in the Chinese market and conduct clinical trials focused on additional indications for Etuary and F351. In medical device operations, based in the United States, we manufacture and sell medical devices, including biomaterials, developed independently by our group.」
The group retained its two-business structure while increasing its consolidated subsidiaries to 10 and adding new drug discovery-related companies, including Cullgen. - FY2018-Q2RestatedAnnual report
「Our group consists of the company filing consolidated financial statements (the Company) and nine consolidated subsidiaries, and its business operations are classified into pharmaceutical operations and medical device operations. In pharmaceutical operations, we manufacture and sell Etuary in the Chinese market and conduct clinical trials focused on additional indications for Etuary and F351. In medical device operations, based in the United States, we manufacture and sell medical devices, including biomaterials, developed independently by our group.」
The group continues to operate through two businesses, pharmaceuticals and medical devices, handling Etuary and development products in China and biomaterials in the United States. - FY2018-Q1RestatedAnnual report
「Our group consists of the company filing consolidated financial statements (the Company) and eight consolidated subsidiaries, and its business operations are classified into pharmaceutical operations and medical device operations. In pharmaceutical operations, we manufacture and sell Etuary in the Chinese market and conduct clinical trials focused on additional indications for Etuary and F351. In medical device operations, based in the United States, we manufacture and sell medical devices, including biomaterials, developed independently by our group.」
The group continues to operate through two businesses, pharmaceuticals and medical devices, handling Etuary and development products in China and biomaterials in the United States. - FY2017RestatedAnnual report
「Our group has two business segments: pharmaceutical operations, centered on Etuary sold in the Chinese market and the investigational compound F351, and medical device operations based in the U.S. market.」
The group continues to operate through two businesses centered on Etuary in China and biomaterials in the United States. - FY2017-Q3ReframedAnnual report
「Our primary sources of revenue are sales of Etuary, an IPF treatment in our pharmaceutical business in China, and biomaterials in our medical device business in the United States.」
The description of the group's primary revenue sources now explicitly includes biomaterials sales in the United States in addition to Etuary sales in China. - FY2017-Q2RestatedAnnual report
「Our primary source of revenue is sales of Etuary [Chinese: 艾思瑞®, English: Etuary® (generic name: pirfenidone)], a treatment for idiopathic pulmonary fibrosis (IPF) launched in China.」
The group continues to identify Etuary, launched in China, as its primary source of revenue. - FY2017-Q1RestatedAnnual report
「Our primary source of revenue is sales of Etuary [Chinese: 艾思瑞®, English: Etuary® (generic name: pirfenidone)], a treatment for idiopathic pulmonary fibrosis (IPF) launched in China.」
The group continues to identify Etuary, launched in China, as its primary source of revenue. - FY2016-Q2First statedAnnual report
「Our primary source of revenue is sales of Etuary [Chinese: 艾思瑞®, English: Etuary® (generic name: pirfenidone)], a treatment for idiopathic pulmonary fibrosis (IPF) launched in China.」
The group identifies Etuary, launched in China, as its primary source of revenue.